344 related articles for article (PubMed ID: 16283147)
1. Hereditary breast and ovarian cancer: review and future perspectives.
Lux MP; Fasching PA; Beckmann MW
J Mol Med (Berl); 2006 Jan; 84(1):16-28. PubMed ID: 16283147
[TBL] [Abstract][Full Text] [Related]
2. Management updates for women with a BRCA1 or BRCA2 mutation.
Nusbaum R; Isaacs C
Mol Diagn Ther; 2007; 11(3):133-44. PubMed ID: 17570734
[TBL] [Abstract][Full Text] [Related]
3. Prevention and therapy for BRCA1/2 mutation carriers and women at high risk for breast and ovarian cancer.
Kuschel B; Lux MP; Goecke TO; Beckmann MW
Eur J Cancer Prev; 2000 Jun; 9(3):139-50. PubMed ID: 10954253
[TBL] [Abstract][Full Text] [Related]
4. [Clinical and molecular diagnosis of inherited breast-ovarian cancer].
Chompret A
J Gynecol Obstet Biol Reprod (Paris); 2003 Apr; 32(2):101-19. PubMed ID: 12717301
[TBL] [Abstract][Full Text] [Related]
5. Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations.
Casey MJ; Synder C; Bewtra C; Narod SA; Watson P; Lynch HT
Gynecol Oncol; 2005 May; 97(2):457-67. PubMed ID: 15863145
[TBL] [Abstract][Full Text] [Related]
6. Association between clinical characteristics and risk-reduction interventions in women who underwent BRCA1 and BRCA2 testing: a single-institution study.
Uyei A; Peterson SK; Erlichman J; Broglio K; Yekell S; Schmeler K; Lu K; Meric-Bernstam F; Amos C; Strong L; Arun B
Cancer; 2006 Dec; 107(12):2745-51. PubMed ID: 17109443
[TBL] [Abstract][Full Text] [Related]
7. The Preventive Intervention of Hereditary Breast Cancer.
Cao A; Huang L; Shao Z
Adv Exp Med Biol; 2017; 1026():41-57. PubMed ID: 29282679
[TBL] [Abstract][Full Text] [Related]
8. Risk management options elected by women after testing positive for a BRCA mutation.
Garcia C; Wendt J; Lyon L; Jones J; Littell RD; Armstrong MA; Raine-Bennett T; Powell CB
Gynecol Oncol; 2014 Feb; 132(2):428-33. PubMed ID: 24355485
[TBL] [Abstract][Full Text] [Related]
9. Experience of risk-reducing salpingo-oophorectomy for a BRCA1 mutation carrier and establishment of a system performing a preventive surgery for hereditary breast and ovarian cancer syndrome in Japan: our challenges for the future.
Hirasawa A; Masuda K; Akahane T; Tsuruta T; Banno K; Makita K; Susumu N; Jinno H; Kitagawa Y; Sugano K; Kosaki K; Aoki D
Jpn J Clin Oncol; 2013 May; 43(5):515-9. PubMed ID: 23487443
[TBL] [Abstract][Full Text] [Related]
10. [Prophylactic surgery of mammary and ovarian carcinoma].
Lux MP; Bani MR; Fasching PA; Beckmann MW
Chirurg; 2005 Dec; 76(12):1145-54. PubMed ID: 16237564
[TBL] [Abstract][Full Text] [Related]
11. Hereditary ovarian cancers: from BRCA mutations to clinical management. A modern appraisal.
Tinelli A; Malvasi A; Leo G; Vergara D; Pisanò M; Ciccarese M; Chiuri VE; Lorusso V
Cancer Metastasis Rev; 2010 Jun; 29(2):339-50. PubMed ID: 20405170
[TBL] [Abstract][Full Text] [Related]
12. Individualized preventive and therapeutic management of hereditary breast ovarian cancer syndrome.
Roukos DH; Briasoulis E
Nat Clin Pract Oncol; 2007 Oct; 4(10):578-90. PubMed ID: 17898808
[TBL] [Abstract][Full Text] [Related]
13. Effect of Oophorectomy on Survival After Breast Cancer in BRCA1 and BRCA2 Mutation Carriers.
Metcalfe K; Lynch HT; Foulkes WD; Tung N; Kim-Sing C; Olopade OI; Eisen A; Rosen B; Snyder C; Gershman S; Sun P; Narod SA
JAMA Oncol; 2015 Jun; 1(3):306-13. PubMed ID: 26181175
[TBL] [Abstract][Full Text] [Related]
14. Hereditary breast-ovarian cancer: clinical findings and medical management.
Marshall M; Solomon S
Plast Surg Nurs; 2007; 27(3):124-7. PubMed ID: 17901820
[TBL] [Abstract][Full Text] [Related]
15. SEOM clinical guidelines in Hereditary Breast and ovarian cancer.
Llort G; Chirivella I; Morales R; Serrano R; Sanchez AB; Teulé A; Lastra E; Brunet J; Balmaña J; Graña B;
Clin Transl Oncol; 2015 Dec; 17(12):956-61. PubMed ID: 26669313
[TBL] [Abstract][Full Text] [Related]
16. [BRCA1- and BRCA2 mutations: Clinical management of patients with hereditary breast and ovarian cancer].
Pristauz G; Geigl JB; Petru E
Wien Med Wochenschr; 2010 Apr; 160(7-8):158-62. PubMed ID: 20473725
[TBL] [Abstract][Full Text] [Related]
17. Familial breast and ovarian cancers.
Arai M; Utsunomiya J; Miki Y
Int J Clin Oncol; 2004 Aug; 9(4):270-82. PubMed ID: 15375703
[TBL] [Abstract][Full Text] [Related]
18. Four new cases of double heterozygosity for BRCA1 and BRCA2 gene mutations: clinical, pathological, and family characteristics.
Zuradelli M; Peissel B; Manoukian S; Zaffaroni D; Barile M; Pensotti V; Cavallari U; Masci G; Mariette F; Benski AC; Santoro A; Radice P
Breast Cancer Res Treat; 2010 Nov; 124(1):251-8. PubMed ID: 20373018
[TBL] [Abstract][Full Text] [Related]
19. Time to incorporate germline multigene panel testing into breast and ovarian cancer patient care.
Graffeo R; Livraghi L; Pagani O; Goldhirsch A; Partridge AH; Garber JE
Breast Cancer Res Treat; 2016 Dec; 160(3):393-410. PubMed ID: 27734215
[TBL] [Abstract][Full Text] [Related]
20. Central European BRCA2 mutation carriers: birth cohort status correlates with onset of breast cancer.
Tea MK; Kroiss R; Muhr D; Fuerhauser-Rappaport C; Oefner P; Wagner TM; Singer CF
Maturitas; 2014 Jan; 77(1):68-72. PubMed ID: 24156927
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
